NCT02176577撤回3 期
An Open-Label, Multi-Center Study to Determine the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Phamacokinetic sampling
研究概览
简要总结
The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.
详细描述
Treament medication will be administered topically twice daily for 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of Atopic Dermatitis
- •Good health with the exception of Atopic Dermatitis
- •Percent body surface area minimums
排除标准
- •Subject who are nursing, pregnant or planning a pregnancy
研究组 & 干预措施
Product 0405
Experimental
Topically Active Investigational Product 0405
干预措施: Product 0405 (Drug)
结局指标
主要结局
Phamacokinetic sampling
时间窗: 28 days
次要结局
- Laboratory tests, vital signs, adverse events and local skin safety signs(28 days)
研究者
相似试验
已完成
4 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric PatientsPathological ProcessesNCT01092754Guerbet100
已完成
3 期
Study of PlasmaCap IG in Adults and Children With PIDDPrimary Immune Deficiency Diseases (PIDD)NCT03238079Evolve Biologics63
招募中
2 期
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06055959UCB Biopharma SRL8
撤回
2 期
Efficacy and Safety of MAA868 in Patients With Atrial FibrillationAtrial FibrillationNCT03398434Novartis Pharmaceuticals
已完成
3 期
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related DiseasesGastric Ulcer (GU)Duodenal Ulcer (DU)Anastomotic Ulcer (AU)Non-erosive Reflux Esophagitis Disease (NERD)Reflux Esophagitis (RE)Zollinger-Ellison SyndromeNCT02153398AstraZeneca55